Scarica l'app Stockscreener
11.90
3.57%
-0.44
Dopo l'orario di chiusura:
12.18
0.28
+2.35%
Precedente Chiudi:
$12.34
Aprire:
$12.1
Volume 24 ore:
334.87K
Relative Volume:
2.01
Capitalizzazione di mercato:
$4.04B
Reddito:
$804.63M
Utile/perdita netta:
$-7.13M
Rapporto P/E:
-563.98
EPS:
-0.0211
Flusso di cassa netto:
$-73.42M
1 W Prestazione:
+1.36%
1M Prestazione:
+0.93%
6M Prestazione:
+50.63%
1 anno Prestazione:
+22.81%
Intervallo 1D:
$11.88
$12.20
Intervallo di 1 settimana:
$11.84
$12.48
Portata 52W:
$6.28
$12.48
Telix Pharmaceuticals Ltd Adr Stock (TLX) Company Profile
Nome
Telix Pharmaceuticals Ltd Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare TLX vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TLX
Telix Pharmaceuticals Ltd Adr
|
11.90 | 4.19B | 804.63M | -7.13M | -73.42M | -0.0211 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-18 | Iniziato | Citigroup | Buy |
| 2025-08-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-07-03 | Iniziato | H.C. Wainwright | Buy |
| 2025-06-05 | Iniziato | Wedbush | Outperform |
| 2024-11-15 | Iniziato | UBS | Buy |
Telix Pharmaceuticals Ltd Adr Borsa (TLX) Ultime notizie
Telix Pharmaceuticals stock hits 52-week high at 12.48 USD By Investing.com - Investing.com Canada
Two New York conferences will include Telix presentations - Stock Titan
Telix Pharmaceuticals Shares Rise 5.3% as Analyst Highlights BiPASS Trial and FDA Pathway - finance.yahoo.com
Telix Pharmaceuticals stock jumps on trial completion, FDA path By Investing.com - Investing.com Nigeria
Telix Pharmaceuticals stock jumps on trial completion, FDA path - Investing.com
Up to 75% of prostate biopsies are negative. Telix enrolled 350 patients. - Stock Titan
Earnings call transcript: Telix H1 2026 profit jumps as guidance holds - Investing.com
Telix R&D Day to Feature Pipeline Updates and Outside Experts - Stock Titan
Telix Schedules Aug. 20 Webcast for Half-Year Results - Stock Titan
Study Tests Imaging to Select Patients for Telix Prostate Therapy - Stock Titan
ETFs Investing in Telix Pharmaceuticals Limited Sponsored ADR Stocks - TradingView
Telix Pharmaceuticals (TLX) hits US$247M Q2, inks Regeneron deal - Stock Titan
Telix Pharmaceuticals (ASX:TLX) Targets More Than US$1 Billion in Revenue and Other Income After Quarterly Revenue Jumps 21% - Kalkine
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress - GlobeNewswire Inc.
Telix Starts Phase 3 Targeted Radiation Study for Kidney Cancer - Stock Titan
Telix Tests Targeted Therapy Earlier in Metastatic Prostate Cancer - Stock Titan
H.C. Wainwright reiterates Telix Pharmaceuticals stock rating on FDA trial progress - Investing.com
Telix Pharmaceuticals (ASX:TLX): The Nuclear Medicine Company Attracting Significant Investor Attention - Kalkine
Why Is Telix Pharmaceuticals (ASX:TLX) on Investors' Radar Despite a 30% One-Year Decline? - Kalkine
FDA backs Telix (NASDAQ: TLX) ProstACT Global Phase 3 trial design - Stock Titan
Telix Pharmaceuticals (ASX:TLX) in Focus After Positive U.S. Regulatory Update - Kalkine
Telix clears FDA protocol review for prostate cancer trial expansion - Stock Titan
Telix Pharmaceuticals Limited Sponsored ADR Actuals & Estimates (NASDAQ:TLX) - TradingView
Telix webinar spotlights glioblastoma care and theranostics next week - Stock Titan
ASX Healthcare Sector Rally: CSL, ResMed and Telix Advance on Broad Market Strength - Kalkine
AI-enhanced cancer scans: Telix and United Imaging team up on theranostics - Stock Titan
Prostate cancer trial: Telix therapy shows acceptable safety in combo treatment - stocktitan.net
Telix CEO lines up back-to-back investor talks in Chicago and New York - stocktitan.net
TLX - Finviz
TLX SEC FilingsTelix Pharmaceuticals Ltd ADR 10-K, 10-Q, 8-K Forms - Stock Titan
Telix Pharmaceuticals Ltd stock (AU000000TLX2): FDA filing advances - Ad-hoc-news.de
Telix Pharmaceuticals (TLX) furnishes AGM addresses, presentation and results via Form 6-K - Stock Titan
Telix Pharmaceuticals (TLX) director Form 3 shows no share trades - Stock Titan
Telix Pharmaceuticals (TLX) director Jellison files initial Form 3 ownership - Stock Titan
Maria Rivas joins Telix Pharmaceuticals (TLX) board and files initial Form 3 - Stock Titan
Prostate cancer imaging tie-up aims to cut incontinence, impotence risks - Stock Titan
Can Telix Pharmaceuticals (ASX:TLX) Regain Momentum Ahead of Key FDA Decision? - Kalkine
Telix (TLX) CEO boosts indirect stake with 67,935-share open-market buy - Stock Titan
Kidney cancer scan showed 98% positive predictive value in analysis - stocktitan.net
Europe begins 210-day review of Telix brain cancer imaging candidate - Stock Titan
Telix reports dosimetry data for prostate cancer therapy candidate - Investing.com
Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach - Sahm
US$600M Telix Pharmaceuticals (TLX) convertible bond settlement noted - Stock Titan
TLX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Telix Pharmaceuticals (TLX) files 6-K on AGM and proxy materials - Stock Titan
Telix’s Phase 3 prostate cancer study gets a late-breaking ASCO slot - Stock Titan
[6-K] Telix Pharmaceuticals Ltd Current Report (Foreign Issuer) | TLX SEC FilingForm 6-K - Stock Titan
Telix Pharma Gains As Regeneron Tie-Up Targets Solid Tumor Programs - Sahm
First radiopharmaceutical enters Phase 3 for recurrent brain cancer - Stock Titan
Regeneron taps Telix in $40M push for next-generation cancer drugs - Stock Titan
Telix Pharmaceuticals stock gains on FDA acceptance of NDA - Investing.com
Telix Pharmaceuticals Ltd Adr Azioni (TLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):